GRIP Molecular Technologies has developed a novel CRISPR-based diagnostic that enables molecular testing in a simple lateral flow format for both point-of-care (POC) and point-of-need (PON) infectious disease testing. The platform delivers test results comparable to existing POC and lab-based molecular tests in under 15 minutes at room temperature, eliminating the need for specialized equipment or laboratory infrastructure. This breakthrough technology positions GRIP to address the growing demand for rapid, accurate, and accessible molecular diagnostics in diverse healthcare settings.

QV Bioelectronics is developing GRACE, an implantable Tumour Treating Fields (TTF) device platform for treating solid tumours, initially focusing on glioblastoma (GBM). Placed during tumour resection surgery, GRACE delivers targeted TTF from within the body to disrupt cancer cell division, with an implantable design intended to maximise patient quality of life.

Portable organ testing and preservation device with potential to eliminate the years-long waitlist for lifesaving kidney transplants. We recently received an FDA Breakthrough Device Designation based upon our compelling preclinical data vs. the standard of care.

Prometheus Therapeutics has developed the world's first Regenerative Photobiomodulation (PBM) platform to stimulate biologic healing. This is a patent-protected technology platform, and our first mission addresses the most significant unresolved clinical issue in Brain Aneurysm Care: awful long-term occlusion rates.

HapticHeart Solutions is advancing a wearable haptic feedback platform—featuring a glove and armband—that restores tactile sensation in catheter-based, minimally invasive, and robotic procedures. By converting physical and physiological signals into real-time touch and force feedback, the system aims to enhance surgical precision, shorten learning curves, and improve patient outcomes. Currently at Technology Readiness Level 6, the prototype has demonstrated clinical utility in electrophysiology and is being expanded for use in robotic surgery.

May Health is developing a minimally invasive treatment for polycystic ovary syndrome (PCOS), a leading cause of female infertility due to ovulatory dysfunction. Current treatment options—including drug therapy, surgical ovarian drilling, and IVF—carry risks such as multiple pregnancies, invasiveness, and high costs. May Health's approach aims to replicate the effectiveness of ovarian drilling while reducing procedural risk and invasiveness. The goal is to enable more natural conception pathways for women with PCOS.

Percy is a paradigm-shifting contactless, non-video, multi-sensor behavioral sleep monitoring device with thermal, radar, microphones, and environmental sensors and an AI algorithm that intuits behavioral insights in real time. Doctors access a database where they can access a timeline with objective baseline data to identify episodic problematic events that disrupt sleep, discriminate between medical and behavioral sleep challenges, and monitor treatment compliance without patient report.

Radial1 has developed unique endovascular catheter technologies for Neurovascular, Cardiovascular and Peripheral Vascular applications. Full line of stroke aspiration catheters feature the lowest profiles and LARGEST LUMENS in the world. Largest lumen Guide catheters, lowest profile Radial-to-peripheral and Radial-to-brain sheaths, lowest profile diagnostic catheters, and lowest profile access sheaths. Groundbreaking steerable technologies as well. Raising Series A

Preceptis Medical develops technologies that enable pediatric ear tube procedures to be performed in the office without general anesthesia. The Hummingbird® Tympanostomy Tube System (TTS) allows ENTs to place ear tubes efficiently under local anesthesia, eliminating the need for an operating room while maintaining established standards of safety and effectiveness for one of the most common pediatric procedures.

The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body's own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.

Endeavor Orthopaedics is an IP-protected platform technology company focused on the integration of fracture repair with soft tissue management of deforming forces. The combination of plate/screw and suture construct in one implant allows surgeons to address not only the osseous fracture repair but also the soft-tissue deforming forces, creating a bio-mechanical advantage during patient recovery.

InflammaSense is a medical technology company pioneering a first-of-its-kind AI-driven sepsis monitoring platform that combines Autonomic Neurography (ANG) and micro-RNA profiling to continuously track the body's inflammatory signals in real time. This unique platform detects organ-specific infection signals and triggers precise micro-RNA biomarker tests, providing real-time insights that guide tailored treatment decisions for sepsis. By enabling faster sepsis diagnosis, precision therapy guidance, and significant hospital cost savings through shorter hospital stays, InflammaSense delivers improved patient outcomes and a compelling value proposition for healthcare systems.

KiriGenX is developing the first bioinductive collagen implant platform purpose-built for early-stage rotator cuff disease at the articular side. The technology delivers a biologic scaffold to support tendon healing in an underserved patient population and is advancing through a 510(k) pathway, with planned expansion into broader tendon repair indications.

Flow Medical is developing a catheter-directed thrombolysis platform for the treatment of intermediate-risk pulmonary embolism. The device combines thrombolytic drug delivery with continuous pulmonary artery pressure monitoring, enabling real-time assessment of a patient's hemodynamic response during therapy.

Sonion Health is dedicated to revolutionizing hypertension care through our cutting-edge optical biosensing technology and artificial intelligence, enabling a cuffless wearable device that provides continuous access to clinical-grade blood pressure monitoring. This device offers real-time, precise readings throughout daily activities—including sitting, semi-fowler, and supine—setting new benchmarks in hypertension diagnosis, remote patient monitoring (RPM), and inpatient care.

A minimally invasive, lung-sparing device that will provide physicians and patients with the certainty they need to move forward with treatment.

Agents of Discovery empowers health and life sciences organizations, cities, universities, airports, sports teams, and other innovation hubs to create place-based learning experiences guided by interactive, AI-powered avatars. Using the Agents platform, teams can support education, workforce training, and community engagement while transforming indoor and outdoor spaces into dynamic, interactive adventures.

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Liquet Medical is developing catheter-based technology for the treatment of pulmonary embolism (PE). Our Versus™ Catheter combines bilateral pulmonary artery drug delivery with continuous, real-time pulmonary artery pressure monitoring through a single venous access, enabling physicians to assess hemodynamic response during catheter-directed thrombolysis.

Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company's portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures.

Realize Medical makes patient-specific planning easy with, FDA-cleared Elucis, the world's first all-in-one VR-based medical modeling and collaboration platform. Elucis is a mixed reality software platform for surgical planning that transforms medical images into interactive 3D models. It enables clinicians to visualize, design, and plan complex procedures with precision and collaboration, improving understanding, communication, and patient outcomes.

AVeta Medical is developing a non-hormonal, minimally invasive device therapy that uses gentle negative pressure to restore and maintain vaginal tissue health and relieve genitourinary symptoms of menopause. Designed for convenient use and durable symptom control, it targets the underlying tissue changes of menopause without hormones or energy-based ablation. Despite the high prevalence of GSM, many women remain undertreated due to limitations, contraindications, or dissatisfaction with current options—creating a substantial unmet need for effective, hormone-free solutions.